Related Experiment Video
Updated: Dec 22, 2025
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.3K
Antithrombotic Treatment in Cardiomyopathies
Georgia Vogiatzi1, Antonios Pantazis2, Dimitris Tousoulis1
1First Department of Cardiology, 'Hippokration' Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Current Pharmaceutical Design
|May 1, 2020
Summary
Cardiomyopathies, a cause of heart failure, have unclear antithrombotic therapy benefits for preventing blood clots. More research is needed to determine the risk-benefit ratio for these patients.
Area of Science:
- Cardiology
- Thrombosis Research
Background:
- Cardiomyopathies are a diverse group of heart muscle diseases leading to heart failure.
- Existing evidence on heart failure in cardiomyopathies is growing, but therapeutic strategies require clarification.
Purpose of the Study:
- To review epidemiologic, pathophysiologic, clinical, and therapeutic data on thromboembolism prevention in heart failure due to cardiomyopathies.
- To address the lack of consensus regarding antithrombotic therapy in cardiomyopathies without primary valvular disease or atrial fibrillation.
Main Methods:
- This is a review article.
- It synthesizes existing data on thromboembolism in cardiomyopathies.
Main Results:
- Observational data suggest an increased venous thromboembolic risk in cardiomyopathies.
- The precise role and risk:benefit ratio of antithrombotic therapy remain unclear in this patient population.
Conclusions:
- Antithrombotic therapy's efficacy in preventing thromboembolic events in cardiomyopathies without atrial fibrillation or valvular disease is not established.
- Further investigation is warranted to guide therapeutic decisions for thromboembolism prevention in heart failure patients with cardiomyopathies.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
219
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
219
01:14Myocarditis III: Medical Management
117
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
117
01:30Cardiomyopathy II: Dilated Cardiomyopathy
335
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
335
01:26Heart Failure Drugs: Inotropic Agents
1.1K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
01:28Acute Coronary Syndrome IV: Interprofessional Care
164
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
164
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
278
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
278